Should adult tetanus immunization be given as a single vaccination at age 65? - A cost-effectiveness analysis

Journal of General Internal Medicine

Volumn 8, Issue 8, 1993, Pages 405-412

  Balestra, Dominic J ^a   Uttenberg, Benjamin ^b  

^a Department of Veterans Affairs Regional Office White River Junction   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

cost benefit analysis; immunization policy; preventive medicine; tetanus; vaccines

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; IMMUNE STATUS; PATIENT COMPLIANCE; TETANUS; TETANUS PROPHYLAXIS; VACCINATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COMPARATIVE STUDY; COST-BENEFIT ANALYSIS; HUMAN; IMMUNIZATION, SECONDARY; MIDDLE AGE; MODELS, STATISTICAL; SUPPORT, NON-U.S. GOV'T; TETANUS; TETANUS TOXOID; VALUE OF LIFE;

EID: 0027201514     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/BF02599616     Document Type: Article

References (49)

1. Immunization policies and vaccine coverage among adults
2. Critical review of adult health maintenance, Part 2. Prevention of infectious diseases
3. General recommendations on immunization
4. Immunizations, immuno-prophylaxis, and chemo-prophylaxis to prevent selected infections
5. Diphtheria, tetanus and pertussis: guidelines for vaccine prophylaxis and other preventive measures
6. Cost-effectiveness of primary tetanus vaccination among elderly Canadians
7. Molecular epidemiology of the 1984–1986 outbreak of diphtheria in Sweden
8. Diphtheria outbreaks in immunized populations
9. Diphtheria in immunized populations
10. Diphtheria in immunized populations
11. Diphtheria among alcoholic urban adults. A decade of experience in Seattle
12. Immunity to diphtheria and tetanus in inner-city women of childbearing age
13. Specific prophylaxis of tetanus
14. Tetanus despite pre-existing antitetanus antibody
15. Clinical tetanus despite a “protective” level of toxin-neutralizing antibody
16. Neonatal tetanus despite protective serum antitoxin concentration
17. Tetanus and diphtheria immunity in urban Minnesota adults
18. Antitoxin responses in the elderly to tetanus-diphtheria (Td) immunization
19. Tetanus and diphtheria immunity in an elderly population in Los Angeles County
20. Immunity against tetanus and response to revaccination in surgical patients more than 50 years of age
21. Antibody response to successive booster doses of tetanus toxoid in adults
22. Immunity against tetanus and effect of revaccination 25–30 years after primary vaccination
23. Tetanus toxoid emergency boosters. A reappraisal
24. Duration of immunity after active immunization against tetanus
25. Single-dose immunization of human subjects against tetanus
26. Active immunization against tetanus in man. I. Duration of anamnestic reaction after one dose of vaccine
27. Tetanus—United States, 1982–1984
28. Tetanus—a method of scoring to determine prognosis
29. Intensive care in tetanus: management, complications, and mortality in 100 cases
30. Diphtheria-tetanus over-immunization in children with no records: can it be prevented?
31. Tetanus—United States, 1985–1986
32. Tetanus immunization of adult members of an HMO
33. Assessment of vital statistics and surveillance data for monitoring tetanus mortality, United States, 1979–1984
34. Reactions after plain and adsorbed tetanus vaccines
35. Tetanus toxoid: what determines reaction proneness
36. Systemic reactions during cutaneous testing for tetanus toxoid hypersensitivity
37. Adverse effects of immunization
38. Excessive use of tetanus toxoid boosters
39. Adverse reactions to tetanus toxoid
40. The Markov process in medical prognosis
41. Status of immunity to tetanus, measles, mumps, rubella, and polio among U.S. travelers
42. Adult immunizations: are they worth the trouble?
43. Implementing preventive services: success and failure in an outpatient trial
44. Screening for hypertension
45. Natural resistance against tetanus in patients with lepromatous leprosy
46. Response to single dose of tetanus vaccine in subjects with naturally acquired tetanus antitoxin
47. Natural tetanus immunity in lepromatous leprosy patients